Pharmaceuticals & Therapeutics

A large-scale analysis reveals that tenapanor, known as IBSRELA, provides quicker relief from constipation and abdominal pain for adults with IBS-C.

Emalex Biosciences offers its investigational drug ecopipam to Tourette syndrome patients out of options, signaling a potential shift in treatment.

A massive investment in Kankakee promises hundreds of jobs and a vital increase in life-saving plasma therapies for patients with rare diseases.

A landmark European approval for Elfabrio allows stable Fabry disease patients to switch to monthly infusions, promising greater freedom and lower healthcare strain.

A new drug, CRS3123, not only cures C. difficile but drastically cuts recurrence rates by preserving the gut microbiome, a major leap over standard care.

A year after rebranding from FibroGen, Kyntra Bio's first full-year report will test if its lean strategy can fuel its ambitious oncology pipeline.

A strategic partnership with Tenacia gives Rapport's novel CNS drug, RAP-219, a path into Greater China, backed by strong Phase 2 data and non-dilutive funding.

A new study finds Reiki therapy doesn't reduce pre-surgery anxiety for wisdom tooth removal, but it may offer a slight edge in postoperative pain.

A new drug for Raynaud's phenomenon in scleroderma patients significantly boosts attack-free days, offering hope despite missing its primary trial goal.

Artelo Biosciences executes a reverse stock split to fight delisting, but will the financial maneuver be enough to fund its promising drug pipeline?

Allarity Therapeutics lands a crucial $20M debt deal to push its unique ovarian cancer drug, stenoparib, through late-stage trials and extend its runway to 2028.

Brazilian aerospace giant Embraer shatters financial records and builds its largest-ever order book, signaling a robust recovery in global aviation.

Scientists find herpes melts the inside of our cells to replicate faster, a discovery that could revolutionize treatments for a host of viral diseases.

BioRestorative Therapies is leveraging its clinical-grade regenerative medicine to disrupt the aesthetics industry. Can science beat marketing?

The biotech firm accelerates a key trial but faces a partner loss, widening losses, and a CEO search, putting its promising siRNA pipeline at a crossroads.

With a total of $160M in Series B funding, Atavistik Bio is advancing its selective allosteric inhibitors for rare diseases HHT and MPNs.

Investors watch closely as CytoSorbents balances a push for profitability with high-stakes regulatory hurdles for its life-saving blood purification tech.

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

K-beauty giant COSRX and fashion house Courrèges reunite at PFW, unveiling an exclusive kit that signals a new era for luxury skincare on the runway.

OmniAb reported declining revenue and a wider net loss for 2025, even as it launched its revolutionary OmniUltra platform and its partners' drugs advance.